Navigation Links
Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
Date:11/7/2007

ents with AF/atrial flutter given vernakalant (45 percent) demonstrated conversion to SR within 90 minutes compared to patients given placebo (15 percent), p=.0002. In the subset of patients with AF at baseline, conversion was observed in 47 percent treated with vernakalant compared with 14 percent given placebo, p=.0001. Median time to conversion among vernakalant responders was 12 minutes and SR was maintained for patients with AF/atrial flutter for 24 hours in 60 percent and for seven days in 57 percent. Seventy-five percent of vernakalant responders required only one dose of drug. Vernakalant is not effective in atrial flutter.

The most common adverse events (AEs) in patients given vernakalant were AF (20 percent), nausea (6 percent), constipation (5 percent), weight increase (5 percent) and dyspnea (5 percent). Rates of serious AEs over the entire study were similar with placebo (11 percent) and vernakalant (9 percent). In the first 24 hours, only 2 patients (2 percent) given vernakalant experienced a serious AE (complete AV block and hypotension). There were no deaths or cases of torsade de pointes.

About Atrial Fibrillation

AF is an interruption of the normal sinus rhythm (arrhythmia) of the heart in which the atria, the two uppermost chambers of the heart, beat irregularly and at an extremely rapid rate(1). During AF, rapid and uncoordinated electrical discharges are generated by the heart's natural pacemaker (sinoatrial node) and other parts of the atria. This causes ineffective contractions of the atria and reduces the ability of the heart to pump blood through the body. Symptoms include dizziness, heart palpitations, weakness, shortness of breath and angina (chest pain)(1). The number of AF patients is expected to triple over the next 50 years due to the increased prevalence of risk factors including hypertension, obesity, diastolic dysfunction, inflammation, diabetes and sleep apnea(2).

About Astellas

Astellas Pharma US, Inc
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... 16, 2015 Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, announced today that ... Commission an Annual Report on Form 20-F that included ... 2014. An electronic version of Mindray,s Annual Report ... relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
(Date:4/16/2015)... 2015 Mallinckrodt plc (NYSE: MNK ... that it has completed its acquisition of Ikaria, ... billion. The Ikaria acquisition extends Mallinckrodt,s footprint in ... neonatal critical care with INOMAX ® (inhaled ... highly vulnerable patient population. It also accelerates Mallinckrodt,s ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5
... FRANCISCO, Oct. 30 CCBR-SYNARC, the world,s leading provider ... center services to the pharmaceutical and biotechnology industries, announced ... for use in imaging clinical trials. , SYNARC has ... 2004. With the release of the enhanced SynarcConnect(SM) ...
... Inc. announced the re-launch of its changing possibilities ... Web site and a new community on Facebook®. People ... Nordisk is committed to helping this community realize that ... new online resources were created to engage and connect ...
Cached Medicine Technology:CCBR-SYNARC Expands Electronic Data Capture Capabilities 2Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed Royce ... 1849 in congress on April 16, 2015 in an ... with the genetic disease. , The bill, similar ... first to create a federally led and financed initiative ... telangiectasia. This would effectively prevent premature death and disability ...
(Date:4/17/2015)... Most dental patients are not aware ... made overseas by foreign dental laboratories, according to the ... in more than 40 states by their respective state ... Dental Laboratories has created the “What’s In ... about the consequences that could be associated with using ...
(Date:4/17/2015)... 2015 Scientists from the Icahn ... of U.S. and Venezuelan researchers, have discovered the ... among an isolated tribe of Yanomami Amerindians in ... in the Yanomami, previously unexposed to antibiotics or ... that of people living in industrialized countries, and ...
(Date:4/17/2015)... 2015 Compare-autoinsurance.org has released a new ... online auto insurance quotes . , The online ... for their cars. Drivers should always compare multiple car ... insurance market is a competitive one, which means that ... , It is now possible to compare online ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2
... developed by an immunologist Dr Brendan O'Sullivan of Brisbane, for ... skyrocketing rates// of medicines that is available for diabetes in ... UQ's Centre for Immunology and Cancer Research (CICR) are developing ... in obesity -- a common precursor to diabetes, reports foodconsumer.org. ...
... a million lives owing to treatment costs that very many ... Asia and Africa seem to be at the receiving end. ... coming out with a facility that would enable mass production ... capacity to lower the costs of each dose by 25 ...
... Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' ... patients//, suffering from lung cancer. ,The Managing Director ... tablet taken once a day and has the potential ... patients with locally advanced or metastatic Non-Small Cell Lung ...
... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
... methods it ahs been found that survival rates following ... when emergency medical// personnel used a new form of ... Center. ,Cardiocerebral Resuscitation, is how this new approach is ... procedures. , ,In the words of Michael J. ...
... at assuming the role of a doctor but pretty bad ... University// of Technology has revealed that nearly half of all ... almost always higher than it should be. ,Over medication ... of overmedication have risen from 12% in 1987 to 33 ...
Cached Medicine News:Health News:Type 2 Diabetes Could Be Tackled Using Curry Colouring and Fat Mix 2Health News:Paramedics save more lives following unconventional rules 2
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: